Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

G 207

Next Previous
Drug Profile

G 207

Alternative Names: G207; HSV G207

Latest Information Update: 10 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University Medical Center
  • Developer MediGene Inc
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Medulloblastoma; Ependymoma; Neuroectodermal tumours
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioma

Most Recent Events

  • 10 Dec 2024 G 207 receives Orphan Drug status for Medulloblastoma in USA
  • 04 Dec 2024 G 207 receives Fast Track designation for Glioma [Intratumoural,Injection] (In adolescents, In children, Second-line therapy or greater) in USA
  • 04 Dec 2024 G 207 receives Orphan Drug status for Ependymoma in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top